奥希替尼治疗非小细胞肺癌患者的耐药机制研究进展
2020-12-23王会宜康小红
王会宜 康小红
[摘要] 奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)。目前被批准用于EGFR突变晚期非小细胞肺癌(NSCLC)患者的一线治疗及第一代EGFR-TKIs治疗进展后伴有T790M突变NSCLC的二线治疗。临床研究显示,奥希替尼能够明显改善NSCLC患者的无进展生存期(PFS),但同时也带来了严重的耐药问题。近年来研究发现,一线应用奥希替尼的耐药机制主要有依赖EGFR通路、旁路信号通路的激活;二线及二线后应用奥希替尼所产生的耐药机制有依赖EGFR通路、旁路信号通路的激活,细胞表型转化。不同的用药时间产生的耐药机制有所不同。本文将从临床用药时间角度对奥希替尼耐药机制及治疗策略进行综述,以期为防治或延缓奥希替尼耐药提供理论依据。
[关键词] 非小细胞肺癌;奥希替尼;耐药
[中图分类号] R73 [文献标识码] A [文章编号] 1673-7210(2020)10(a)-0032-04
Research progress on the drug resistance mechanism of Osimertinib in patients with non-small cell lung cancer
WANG Huiyi KANG Xiaohong
Department of Oncology, the First Affiliated Hospital of Xinxiang Medical College, He′nan Province, Xinxiang 453100, China
[Abstract] Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). It is currently approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutation and second-line treatment with T790M mutant NSCLC after the first-generation EGFR-TKIs treatment progresses. Clinical studies have shown that Osimertinib can significantly improve the progression-free survival (PFS) of NSCLC patients, but it also brings serious drug resistance problems. In recent years, studies have found that the first-line application of Osimertinib resistance mechanism mainly depends on the activation of EGFR pathway and bypass signaling pathway; the drug resistance mechanism produced by the second-line and second-line application of Osimertinib depends on the activation of the EGFR pathway, the bypass signaling pathway, and the transformation of the cell phenotype. Osimertinib has different drug resistance mechanisms at different times. In order to provide a theoretical basis for the prevention and treatment of Osimertinib resistance, this article will review the different drug resistance mechanisms and treatment strategies of Osimertinib from the perspective of clinical drug use time.
[Key words] Non-small-cell-lung cancer; Osimertinib; Resistance
第三代表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)——奥希替尼,用于第一代EGFR-TKIs耐药后并且携带T790M突变的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者。AURA3研究顯示[1],与铂类加培美曲塞的化疗比较,奥希替尼在一代EGFR-TKIs治疗肺腺癌耐药后且携带T790M突变患者的二线治疗效果显著,无进展生存期(progression free survival,PFS)延长。临床研究显示,与第一代EGFR-TKIs比较,奥希替尼能够明显延长NSCLC患者的PFS[2]。然而,部分患者在应用奥希替尼治疗后均不可避免地产生了耐药[3]。不同的用药时间所产生的耐药机制不同,一线应用奥希替尼与二线及二线以后使用产生的耐药机制不同。因此,为进一步明确二者差别,现就奥希替尼耐药机制综述如下:……p>
